First Detailed Analysis Of Immune Response To SARS-CoV-2 Bodes Well For COVID-19 Vaccine Development
May 17, 2020
La Jolla, CA – Scientists around the world are racing to develop a vaccine to protect against COVID-19 Coronavirus infection, and epidemiologists are trying to predict how the coronavirus pandemic will unfold until such a vaccine is available.
Yet, both efforts are surrounded by unresolved uncertainty whether the immune system can mount a substantial and lasting response to SARS-CoV-2 and whether exposure to circulating common cold coronaviruses provides any kind of protective immunity.
Study finds robust antiviral T cell response in humans with COVID-19 Coronavirus and detects substantial crossreactivity in unexposed individuals; in a piece of good news provides a benchmark for testing of vaccine candidates.
